KIND-002 is expected to be a major new therapy for severe cutaneous diseases in dogs
SAN FRANCISCO, California. (February 3, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-002. KIND-002 is a potent molecule being developed for severe dermatological diseases in dogs.
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Russell Radefeld/wp-content/uploads/2017/09/KindredBioHeader2017.pngRussell Radefeld2013-02-03 17:45:312014-08-17 17:57:33KindredBio Announces Filing of an Investigational New Animal Drug Application for KIND-002
0.31 (4.45%)
